<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00144261</url>
  </required_header>
  <id_info>
    <org_study_id>1100.1426</org_study_id>
    <nct_id>NCT00144261</nct_id>
  </id_info>
  <brief_title>An Open-label, Non-randomized, Single-arm Study to Investigate the Mechanism(s) by Which Nevirapine Increases Plasma HDL in HIV+ Subjects</brief_title>
  <official_title>An Open-label, Non-randomized, Single-arm Study, to Investigate the Mechanism(s) by Which Nevirapine Increases Plasma High Density Lipoproteins Concentration in HIV+ Subjects Treated With VIRAMUNEÂ® Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      1. In order to obtain further insight as to how NVP affects HDL metabolism, the in vivo&#xD;
           kinetics of the HDL apolipoprotein, Apo A-1, before and 6 weeks after initiation of NVP&#xD;
           containing treatment were evaluated. In addition, the activity of the key enzymes&#xD;
           related to HDL metabolism were assessed.&#xD;
&#xD;
           [ Designated as safety issue: No ]&#xD;
&#xD;
        2. In order to determine the relevance of the HDL increase in decreasing cardiovascular&#xD;
           risk in HIV-positive subjects we evaluated endothelial function (FMD) as a surrogate&#xD;
           marker for cardiovascular disease in patients.&#xD;
&#xD;
      [ Designated as safety issue: No ]&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Prevention</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change of fractional synthetic rate (FSR) of Apo A-1</measure>
    <time_frame>after 6 weeks of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage change of flow mediated dilatation (FMD)</measure>
    <time_frame>after 6 and 24 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change in the proteins involved in HDL metabolism</measure>
    <time_frame>after 6 and 24 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage change in plasma levels of lipoproteins in the fasting lipid panel (TC, LDL, HDL, TG) from Week 0 (baseline) to 6 and 24 weeks of treatment with NVP-based antiretroviral therapy</measure>
    <time_frame>from week 0 to 6, and 24 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage change in activity (and/or mass) of the constituents of the lipid enzymes panel from Week 0 to 24 weeks of NVP-based antiretroviral therapy</measure>
    <time_frame>from week 0 to 24 weeks of treatment</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">15</enrollment>
  <condition>HIV Infections</condition>
  <condition>Metabolism, Lipids</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nevirapine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients will be included when they meet the following criteria:&#xD;
&#xD;
          1. 18 years of age or older.&#xD;
&#xD;
          2. Ability and willingness to provide signed and dated written informed consent prior to&#xD;
             admission to the study in accordance with GCP and local legislation.&#xD;
&#xD;
          3. Patients on stable therapy with Trizivir only (or its equivalent component drugs), for&#xD;
             at least 6 months prior to screening.&#xD;
&#xD;
          4. Patients with plasma HIV-1-RNA &lt;=50 copies/mL documented on at least two occasions&#xD;
             within 6 months prior to enrollment.&#xD;
&#xD;
          5. Documentation of plasma HIV-1 RNA of &lt;=50 copies/mL for &gt;=6 months while on Trizivir&#xD;
             without other antiretroviral agent. Documentation will include dates and results of&#xD;
             all viral load testing from the previous six months.&#xD;
&#xD;
          6. Ability and willingness to complete the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients will not be included when they meet one or more of the following criteria:&#xD;
&#xD;
          1. Previous exposure to NNRTI drugs.&#xD;
&#xD;
          2. Documented diabetes mellitus.&#xD;
&#xD;
          3. Documented hypertension (systolic &gt;155 mmHg and/or diastolic &gt;95 mmHg).&#xD;
&#xD;
          4. Fasting hypertriglyceridemia (&gt;5.6 mmol/L or 500 mg/dl).&#xD;
&#xD;
          5. Use of lipid-lowering medication during the 90 days prior to study enrollment.&#xD;
&#xD;
          6. Chronic active hepatitis B and/or C infection by history.&#xD;
&#xD;
          7. Anemia (Hb &lt;7.0 mmol/l or 11 g/dl hematocrit &lt;32%).&#xD;
&#xD;
          8. Active opportunistic infection or neoplasm within 3 months prior to screening visit&#xD;
             with the exception of cutaneous Kaposi's sarcoma without evidence of progressive&#xD;
             disease.&#xD;
&#xD;
          9. Any history of cardiovascular disease (infarction, heart failure, peripheral vascular&#xD;
             disease, cerebrovascular disease).&#xD;
&#xD;
         10. Hepatic, renal or thyroid abnormalities, as determined significant by the Principal&#xD;
             Investigator.&#xD;
&#xD;
         11. Pregnancy or lactation.&#xD;
&#xD;
         12. Active anticoagulation therapy (coumarin derivates, heparin).&#xD;
&#xD;
         13. History of HIV-2 infection.&#xD;
&#xD;
         14. Female patients with CD4 counts &gt;250 cells/mm3.&#xD;
&#xD;
         15. Male patients with CD4 counts &gt;400 cells/mm3. Others which can not be listed here.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1100.1426.01 Academic Medical Centre</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1426.02 Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1100.1426.44001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1100/1100.1426_U08-3880.pdf</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1100/1100.1426_literature.pdf</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/19667106</url>
    <description>Related Info</description>
  </link>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>September 2, 2005</study_first_submitted>
  <study_first_submitted_qc>September 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2005</study_first_posted>
  <last_update_submitted>December 27, 2017</last_update_submitted>
  <last_update_submitted_qc>December 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

